Last reviewed · How we verify
Gabapentin higher dose
At a glance
| Generic name | Gabapentin higher dose |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Transcranial Magnetic Stimulation Therapy in Neuropathic Painful Spinal Cord Injury Patients (NA)
- High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer (PHASE3)
- Ultrasound-Guided Erectro Spinae Plane Block Versus Stellate Ganglion Block for Patients With Upper Limb Acute Herpes Zoster Pain. (NA)
- Multimodal Nerve Block and Pulse Radiofrequency for Acute Herpes Zoster Pain (NA)
- Effect of PP-01 on Cannabis Withdrawal Syndrome (PHASE2)
- Regional Anesthesia to Relief Zoster Pain (NA)
- Gabapentin for Alcohol Withdrawal Syndrome (PHASE4)
- Tetra-O-Methyl Nordihydroguaiaretic Acid in Treating Patients With Recurrent High-Grade Glioma (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Gabapentin higher dose CI brief — competitive landscape report
- Gabapentin higher dose updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI